What is Biocon Biologics valuation in the buyout deal?

Biocon Biologics is valued at $5.5 billion in the recent buyout transaction.

How is Biocon acquiring minority stakes in Biocon Biologics?

Biocon is using a mix of cash and Biocon shares to acquire the minority stakes.

Who are the minority shareholders in Biocon Biologics being bought out?

Serum Institute Life Sciences, Tata Capital Growth Fund, and Activ Pine LLP are among the minority shareholders.

Home / Business and Economy / Biocon Acquires Full Control of Biosimilars Unit

Biocon Acquires Full Control of Biosimilars Unit

6 Dec

•

Summary

Biocon is acquiring minority stakes in its biosimilars unit.
The deal values Biocon Biologics at a significant $5.5 billion.
Shareholders will receive Biocon shares or cash in the buyout.

Biocon Acquires Full Control of Biosimilars Unit

Biocon Ltd., a prominent Indian pharmaceutical company, has initiated a significant acquisition to gain full ownership of its biosimilars division, Biocon Biologics Ltd. The proposed transaction involves buying out minority shareholders through a combination of cash payments and a swap of Biocon shares for Biocon Biologics shares.

This strategic consolidation values the biosimilars unit at a substantial $5.5 billion, reflecting its growing importance in the global biopharmaceutical market. Biocon will acquire the stakes held by entities including Serum Institute Life Sciences and Tata Capital Growth Fund, streamlining its corporate structure.

The terms of the deal stipulate that for every 100 Biocon Biologics shares, shareholders will receive 70.28 Biocon shares, with each Biocon share valued at 405.78 Indian Rupees. This move is expected to enhance Biocon's strategic flexibility and market position in the competitive biosimilars landscape.